Nippon Shinyaku (4516.T): FDA briefing document for CAP-1002 FDA advisory committee leaves negative impression-20260727

Flash | 27 Jul 2026 10:16:05 ET │ 10 pages Nippon Shinyaku (4516.T) FDA briefing document for CAP-1002 FDA advisory committee leaves negative impresion CITI'S TAKE We see negative news for the investigational CAP-1002, for which Nippon Shinyaku and Capricor Therapeutics have an exclusive partnership to commercialize and distribute for Duchenne muscular dystrophy. The US firm has disclosed legal action against Nippon Shinyaku over commercialization preparations. Ahead of the FDA advisory committee meeting fo ...